The US Food and Drug Administration has approved Pfizer’s QuilliChew ER (methylphenidate hydrochloride, extended release) chewable tablets for treating attention deficit hyperactivity disorder (ADHD). Pfizer now offers two different products for the treatment of ADHD in patients ages 6 years old and above, liquid Quillivant XR (methylphenidate HCl) CII and new QuilliChew ER chewable tablets.

QuilliChew ER is available in multiple dosage strengths with scored tablet options, which enable healthcare professionals to individualize the dose. QuilliChew ER is available in 20 mg scored, 30 mg scored, and 40 mg unscored tablet options that are chewable and can be taken with or without food. QuilliChew ER is expected to be available in pharmacies in the first quarter of 2016.

“Pfizer is pleased to announce that with new QuilliChew ER, and in partnership with Tris Pharma, the developer of ER chewable tablets, we are expanding our offering of ADHD treatments to include extended-release, chewable tablet options,” said Sam Azoulay, senior vice president, chief medical officer, Global Established Pharma, Pfizer, in a company release.

Tris Pharma is a specialty pharmaceutical company based in Monmouth Junction, New Jersey.

Source: Pfizer